News on Hemoglobin from BioPortfolio.com http://www.BioPortfolio.com Consolidated Hemoglobin news from BioPortfolio.com Tue, 09 Feb 2010 22:07:51 GMT en Xoma starts once-a-month diabetes treatment trialhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038024&HITNO=0&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038024&THISHREF=http://c.moreover.com/click/here.pl%3fz2537438808%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038024&HITNO=0&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038024&THISHREF=http://c.moreover.com/click/here.pl%3fz2537438808%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSan Francisco Business Times: Risk for lower extremity amputation high in diabetics with high HbA1chttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037037&HITNO=1&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037037&THISHREF=http://c.moreover.com/click/here.pl%3fz2536866216%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037037&HITNO=1&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037037&THISHREF=http://c.moreover.com/click/here.pl%3fz2536866216%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedWire News: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035675&HITNO=2&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035675&THISHREF=http://c.moreover.com/click/here.pl%3fz2536327334%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035675&HITNO=2&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035675&THISHREF=http://c.moreover.com/click/here.pl%3fz2536327334%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comInterest!ALERT: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034938&HITNO=3&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034938&THISHREF=http://c.moreover.com/click/here.pl%3fz2536058499%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034938&HITNO=3&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034938&THISHREF=http://c.moreover.com/click/here.pl%3fz2536058499%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXBusiness.com: XOMA (XOMA) Begins Enrollment for XOMA 052 Phase 2bhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034901&HITNO=4&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034901&THISHREF=http://c.moreover.com/click/here.pl%3fz2536032150%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034901&HITNO=4&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034901&THISHREF=http://c.moreover.com/click/here.pl%3fz2536032150%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034881&HITNO=5&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034881&THISHREF=http://c.moreover.com/click/here.pl%3fz2536025209%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034881&HITNO=5&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034881&THISHREF=http://c.moreover.com/click/here.pl%3fz2536025209%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034835&HITNO=6&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034835&THISHREF=http://c.moreover.com/click/here.pl%3fz2536001484%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034835&HITNO=6&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034835&THISHREF=http://c.moreover.com/click/here.pl%3fz2536001484%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034679&HITNO=7&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034679&THISHREF=http://c.moreover.com/click/here.pl%3fz2535918473%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034679&HITNO=7&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034679&THISHREF=http://c.moreover.com/click/here.pl%3fz2535918473%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comDMN Newswire: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034607&HITNO=8&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034607&THISHREF=http://c.moreover.com/click/here.pl%3fz2535881134%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034607&HITNO=8&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034607&THISHREF=http://c.moreover.com/click/here.pl%3fz2535881134%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGlobeNewswire via MSN Money: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034573&HITNO=9&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034573&THISHREF=http://c.moreover.com/click/here.pl%3fz2535869394%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034573&HITNO=9&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034573&THISHREF=http://c.moreover.com/click/here.pl%3fz2535869394%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034567&HITNO=10&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034567&THISHREF=http://c.moreover.com/click/here.pl%3fz2535865250%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034567&HITNO=10&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034567&THISHREF=http://c.moreover.com/click/here.pl%3fz2535865250%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034558&HITNO=11&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034558&THISHREF=http://c.moreover.com/click/here.pl%3fz2535860585%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034558&HITNO=11&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034558&THISHREF=http://c.moreover.com/click/here.pl%3fz2535860585%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGlobeNewswire via Yahoo!: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034539&HITNO=12&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034539&THISHREF=http://c.moreover.com/click/here.pl%3fz2535845600%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034539&HITNO=12&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034539&THISHREF=http://c.moreover.com/click/here.pl%3fz2535845600%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStockwatch: XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034532&HITNO=13&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034532&THISHREF=http://c.moreover.com/click/here.pl%3fz2535841609%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034532&HITNO=13&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034532&THISHREF=http://c.moreover.com/click/here.pl%3fz2535841609%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewsBlaze: FDA OKs OC-Sensor Diana Immunoassay Fecal Occult Blood Testhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032994&HITNO=14&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032994&THISHREF=http://c.moreover.com/click/here.pl%3fz2534945621%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032994&HITNO=14&MSIZE=263&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Hemoglobin&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032994&THISHREF=http://c.moreover.com/click/here.pl%3fz2534945621%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comEndoNurse: